Jpmorgan Chase & CO Harvard Bioscience Inc Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 40,943 shares of HBIO stock, worth $17,196. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,943
Previous 113,591
63.96%
Holding current value
$17,196
Previous $239,000
90.38%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding HBIO
# of Institutions
76Shares Held
22.6MCall Options Held
101KPut Options Held
22K-
Amh Equity LTD3.51MShares$1.47 Million2.13% of portfolio
-
Black Rock Inc. New York, NY2.84MShares$1.19 Million0.0% of portfolio
-
Harvey Partners, LLC Tarrytown, NY2.14MShares$899,2610.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.85MShares$778,6340.0% of portfolio
-
Granahan Investment Management, LLC Waltham, MA1.5MShares$630,6330.03% of portfolio
About HARVARD BIOSCIENCE INC
- Ticker HBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 41,636,500
- Market Cap $17.5M
- Description
- Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...